BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 2007;13:431-456. [PMID: 17329355 DOI: 10.1261/rna.459807] [Cited by in Crossref: 170] [Cited by in F6Publishing: 159] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Ghosh M, Ren G, Simonsen JB, Ryan RO. Cationic lipid nanodisks as an siRNA delivery vehicle. Biochem Cell Biol 2014;92:200-5. [PMID: 24840721 DOI: 10.1139/bcb-2014-0027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
2 Watts JK, Yu D, Charisse K, Montaillier C, Potier P, Manoharan M, Corey DR. Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res 2010;38:5242-59. [PMID: 20403811 DOI: 10.1093/nar/gkq258] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
3 Garbacki N, Di Valentin E, Piette J, Cataldo D, Crahay C, Colige A. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009;22:267-78. [PMID: 19327406 DOI: 10.1016/j.pupt.2009.03.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
4 Vicentini FT, Borgheti-Cardoso LN, Depieri LV, de Macedo Mano D, Abelha TF, Petrilli R, Bentley MV. Delivery systems and local administration routes for therapeutic siRNA. Pharm Res 2013;30:915-31. [PMID: 23344907 DOI: 10.1007/s11095-013-0971-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
5 Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010;27:1184-202. [PMID: 20333454 DOI: 10.1007/s11095-010-0112-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
6 Bao Y, Jin Y, Chivukula P, Zhang J, Liu Y, Liu J, Clamme J, Mahato RI, Ng D, Ying W, Wang Y, Yu L. Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes. Pharm Res 2013;30:342-51. [DOI: 10.1007/s11095-012-0874-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
7 Alkhalil A, Strand S, Mucker E, Huggins JW, Jahrling PB, Ibrahim SM. Inhibition of monkeypox virus replication by RNA interference. Virol J 2009;6:188. [PMID: 19889227 DOI: 10.1186/1743-422X-6-188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
8 Musacchio T, Vaze O, D'Souza G, Torchilin VP. Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug Chem 2010;21:1530-6. [PMID: 20669936 DOI: 10.1021/bc100199c] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 6.3] [Reference Citation Analysis]
9 Pratap A, Singh S, Mundra V, Yang N, Panakanti R, Eason JD, Mahato RI. Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J Drug Target. 2012;20:770-782. [PMID: 22994359 DOI: 10.3109/1061186X.2012.719900] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
10 Mochizuki S, Sakurai K. A Novel Polysaccharide/Polynucleotide Complex and its Application to Bio-functional DNA Delivery System. Polym J 2009;41:343-53. [DOI: 10.1295/polymj.pj2008309] [Cited by in Crossref: 14] [Article Influence: 1.1] [Reference Citation Analysis]
11 McGinnis AC, Grubb EC, Bartlett MG. Systematic optimization of ion-pairing agents and hexafluoroisopropanol for enhanced electrospray ionization mass spectrometry of oligonucleotides. Rapid Commun Mass Spectrom 2013;27:2655-64. [PMID: 24591027 DOI: 10.1002/rcm.6733] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
12 Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv 2008;5:1301-11. [PMID: 19040393 DOI: 10.1517/17425240802568505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
13 Xie H, Sun L, Lodish HF. Targeting microRNAs in obesity. Expert Opin Ther Targets 2009;13:1227-38. [PMID: 19650761 DOI: 10.1517/14728220903190707] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
14 Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence 2010;1:4. [PMID: 20226078 DOI: 10.1186/1758-907X-1-4] [Cited by in Crossref: 91] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
15 Sawarkar SP, Yadav V. Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis. Indian J Dermatol Venereol Leprol 2021;87:333-40. [PMID: 33943062 DOI: 10.25259/IJDVL_470_19] [Reference Citation Analysis]
16 Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J Gastroenterol 2011; 17(36): 4090-4098 [PMID: 22039322 DOI: 10.3748/wjg.v17.i36.4090] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
17 Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm Res 2011;28:3043-9. [PMID: 21773853 DOI: 10.1007/s11095-011-0526-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
18 Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226:365-379. [PMID: 22069063 DOI: 10.1002/path.2993] [Cited by in Crossref: 243] [Cited by in F6Publishing: 222] [Article Influence: 22.1] [Reference Citation Analysis]
19 Yuan H, Lanting L, Xu ZG, Li SL, Swiderski P, Putta S, Jonnalagadda M, Kato M, Natarajan R. Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 2008;295:F605-17. [PMID: 18562637 DOI: 10.1152/ajprenal.90268.2008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
20 Musacchio T, Navarro G, Torchilin V. Molecular assemblies for siRNA delivery. Journal of Drug Delivery Science and Technology 2012;22:5-16. [DOI: 10.1016/s1773-2247(12)50001-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Goraczniak R, Behlke MA, Gunderson SI. Gene silencing by synthetic U1 adaptors. Nat Biotechnol 2009;27:257-63. [PMID: 19219028 DOI: 10.1038/nbt.1525] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
22 Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest. 2007;117:3615-3622. [PMID: 18060019 DOI: 10.1172/jci33483] [Cited by in Crossref: 207] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
23 Froehlich E, Mandeville JS, Arnold D, Kreplak L, Tajmir-riahi HA. Effect of PEG and mPEG-Anthracene on tRNA Aggregation and Particle Formation. Biomacromolecules 2012;13:282-7. [DOI: 10.1021/bm2016515] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
24 Krell J, Frampton AE, Jacob J, Castellano L, Stebbing J. miRNAs in breast cancer: ready for real time? Pharmacogenomics 2012;13:709-19. [PMID: 22515613 DOI: 10.2217/pgs.12.15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
25 Ramon A, Bertrand J, Malvy C. Delivery of Small Interfering RNA. A Review and an Example of Application to a Junction Oncogene. Tumori 2008;94:254-63. [DOI: 10.1177/030089160809400218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Dorasamy S, Narainpersad N, Singh M, Ariatti M. Novel targeted liposomes deliver sirna to hepatocellular carcinoma cells in vitro. Chem Biol Drug Des 2012;80:647-56. [PMID: 22783887 DOI: 10.1111/j.1747-0285.2012.01446.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Barik S. Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. Methods Mol Biol 2009;487:331-41. [PMID: 19301655 DOI: 10.1007/978-1-60327-547-7_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
28 Alterman JF, Hall LM, Coles AH, Hassler MR, Didiot MC, Chase K, Abraham J, Sottosanti E, Johnson E, Sapp E, Osborn MF, Difiglia M, Aronin N, Khvorova A. Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain. Mol Ther Nucleic Acids 2015;4:e266. [PMID: 26623938 DOI: 10.1038/mtna.2015.38] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
29 Ishihara T, Goto M, Kodera K, Kanazawa H, Murakami Y, Mizushima Y, Higaki M. Intracellular delivery of siRNA by cell-penetrating peptides modified with cationic oligopeptides. Drug Delivery 2009;16:153-9. [DOI: 10.1080/10717540902722774] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
30 Bøe SL, Hovig E. Enhancing nucleic acid delivery by photochemical internalization. Ther Deliv 2013;4:1125-40. [PMID: 24024512 DOI: 10.4155/tde.13.78] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
31 Nouraee N, Mowla SJ, Calin GA. Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy. Genes Chromosomes Cancer 2015;54:335-52. [PMID: 25832733 DOI: 10.1002/gcc.22244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
32 Ono M, Yamada K, Avolio F, Afzal V, Bensaddek D, Lamond AI. Targeted Knock-Down of miR21 Primary Transcripts Using snoMEN Vectors Induces Apoptosis in Human Cancer Cell Lines. PLoS One 2015;10:e0138668. [PMID: 26405811 DOI: 10.1371/journal.pone.0138668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
33 Singh Y, Tomar S, Khan S, Meher JG, Pawar VK, Raval K, Sharma K, Singh PK, Chaurasia M, Surendar Reddy B, Chourasia MK. Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes. J Control Release 2015;220:368-87. [PMID: 26528900 DOI: 10.1016/j.jconrel.2015.10.050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
34 Chaturvedi K, Ganguly K, Kulkarni AR, Kulkarni VH, Nadagouda MN, Rudzinski WE, Aminabhavi TM. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert Opinion on Drug Delivery 2011;8:1455-68. [DOI: 10.1517/17425247.2011.610790] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 6.6] [Reference Citation Analysis]
35 Matsui M, Sakurai F, Elbashir S, Foster DJ, Manoharan M, Corey DR. Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol 2010;17:1344-55. [PMID: 21168770 DOI: 10.1016/j.chembiol.2010.10.009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
36 Moro M, Di Paolo D, Milione M, Centonze G, Bornaghi V, Borzi C, Gandellini P, Perri P, Pastorino U, Ponzoni M, Sozzi G, Fortunato O. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J Control Release 2019;308:44-56. [PMID: 31299263 DOI: 10.1016/j.jconrel.2019.07.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
37 Qi R, Wu S, Wang Y, Chen J, Xie Z, Huang Y, Jing X. Contribution of cholesterol moieties attached on MPEG-b-PCL-b-PLL to the cell uptake, endosomal escape and gene knockdown of the micelleplexes of siRNA. Chin J Polym Sci 2013;31:912-23. [DOI: 10.1007/s10118-013-1288-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lim YB, Lee E, Yoon YR, Lee MS, Lee M. Filamentous artificial virus from a self-assembled discrete nanoribbon. Angew Chem Int Ed Engl 2008;47:4525-8. [PMID: 18464240 DOI: 10.1002/anie.200800266] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
39 Park JW, Bang E, Jeon EM, Kim BH. Complexation and conjugation approaches to evaluate siRNA delivery using cationic, hydrophobic and amphiphilic peptides. Org Biomol Chem 2012;10:96-102. [DOI: 10.1039/c1ob06042b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
40 Zhong W, Shen WF, Ning BF, Hu PF, Lin Y, Yue HY, Yin C, Hou JL, Chen YX, Zhang JP. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology. 2009;50:1524-1536. [PMID: 19787807 DOI: 10.1002/hep.23189] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
41 Vicentini FTMDC, Depieri LV, Polizello ACM, Ciampo JOD, Spadaro ACC, Fantini MC, Vitória Lopes Badra Bentley M. Liquid crystalline phase nanodispersions enable skin delivery of siRNA. European Journal of Pharmaceutics and Biopharmaceutics 2013;83:16-24. [DOI: 10.1016/j.ejpb.2012.08.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
42 Lee D, Kim D, Mok H, Jeong JH, Choi D, Kim SH. Bioreducible Crosslinked Polyelectrolyte Complexes for MMP-2 siRNA Delivery into Human Vascular Smooth Muscle Cells. Pharm Res 2012;29:2213-24. [DOI: 10.1007/s11095-012-0750-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
43 Volkov AA, Kruglova NS, Meschaninova MI, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides 2009;19:191-202. [PMID: 19344210 DOI: 10.1089/oli.2008.0162] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
44 Raemdonck K, Van Thienen TG, Vandenbroucke RE, Sanders NN, Demeester J, De Smedt SC. Dextran Microgels for Time-Controlled Delivery of siRNA. Adv Funct Mater 2008;18:993-1001. [DOI: 10.1002/adfm.200701039] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
45 Smicius R, Engels JW. Preparation of Zwitterionic Ribonucleoside Phosphoramidites for Solid-Phase siRNA Synthesis. J Org Chem 2008;73:4994-5002. [DOI: 10.1021/jo800451m] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
46 Ali HM, Urbinati G, Raouane M, Massaad-massade L. Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Review of Clinical Pharmacology 2014;5:403-12. [DOI: 10.1586/ecp.12.33] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
47 Arima H, Motoyama K, Higashi T. Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA. Pharmaceuticals (Basel) 2011;5:61-78. [PMID: 24288043 DOI: 10.3390/ph5010061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
48 Kerr TA, Davidson NO. Therapeutic RNA manipulation in liver disease. Hepatology 2010;51:1055-61. [PMID: 19918970 DOI: 10.1002/hep.23344] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
49 Morgan JR, Nguyen DV, Frohman AR, Rybka SR, Zebala JA. Reversible metal-dependent destabilization and stabilization of a stem-chelate-loop probe binding to an unmodified DNA target. Bioconjug Chem 2012;23:2020-4. [PMID: 22989029 DOI: 10.1021/bc3003293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
50 Kokil GR, Veedu RN, Ramm GA, Prins JB, Parekh HS. Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics. Chem Rev 2015;115:4719-43. [PMID: 25918949 DOI: 10.1021/cr5002832] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
51 Bang EK, Jeon EM, Kim W, Lee KH, Kim KT, Kim BH. Tissue specific delivery of estrone-conjugated siRNAs. Mol Biosyst 2013;9:974-7. [PMID: 23037688 DOI: 10.1039/c2mb25258a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
52 Ma J, Huang C, Yao X, Shi C, Sun L, Yuan L, Lei P, Zhu H, Liu H, Wu X, Ning Q, Zhou C, Shen G. Inhibition of hepatitis B virus and induction of hepatoma cell apoptosis by ASGPR-directed delivery of shRNAs. PLoS One 2012;7:e46096. [PMID: 23094023 DOI: 10.1371/journal.pone.0046096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
53 Valencia-serna J, Gul-uludağ H, Mahdipoor P, Jiang X, Uludağ H. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. Journal of Controlled Release 2013;172:495-503. [DOI: 10.1016/j.jconrel.2013.05.014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
54 Juliano RL, Ming X, Nakagawa O, Xu R, Yoo H. Integrin targeted delivery of gene therapeutics. Theranostics 2011;1:211-9. [PMID: 21547161 DOI: 10.7150/thno/v01p0211] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
55 Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F, Brinkmann U. The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. Cancer Genomics Proteomics 2018;15:17-39. [PMID: 29275360 DOI: 10.21873/cgp.20062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
56 Bobkov GV, Mikhailov SN, Van Aerschot A, Herdewijn P. Phosphoramidite building blocks for efficient incorporation of 2′-O-aminoethoxy(and propoxy)methyl nucleosides into oligonucleotides. Tetrahedron 2008;64:6238-51. [DOI: 10.1016/j.tet.2008.04.110] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
57 Navarro G, Essex S, Torchilin VP. The “Non-viral” Approach for siRNA Delivery in Cancer Treatment: A Special Focus on Micelles and Liposomes. In: Erdmann VA, Barciszewski J, editors. DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases. Berlin: Springer Berlin Heidelberg; 2013. pp. 241-61. [DOI: 10.1007/978-3-662-45775-7_10] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
58 Vengut-climent E, Terrazas M, Lucas R, Arévalo-ruiz M, Eritja R, Morales JC. Synthesis, RNAi activity and nuclease-resistant properties of apolar carbohydrates siRNA conjugates. Bioorganic & Medicinal Chemistry Letters 2013;23:4048-51. [DOI: 10.1016/j.bmcl.2013.05.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
59 Aleku M, Fisch G, Möpert K, Keil O, Arnold W, Kaufmann J, Santel A. Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvascular Research 2008;76:31-41. [DOI: 10.1016/j.mvr.2008.02.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
60 Li F, Mahato RI. RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev 2011;63:47-68. [PMID: 21156190 DOI: 10.1016/j.addr.2010.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
61 Mahato RI. Gene expression and silencing for improved islet transplantation. J Control Release 2009;140:262-7. [PMID: 19376168 DOI: 10.1016/j.jconrel.2009.04.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
62 Mahon KP, Love KT, Whitehead KA, Qin J, Akinc A, Leshchiner E, Leshchiner I, Langer R, Anderson DG. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconjug Chem 2010;21:1448-54. [PMID: 20715849 DOI: 10.1021/bc100041r] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
63 Gao W, Xiao Z, Radovic-Moreno A, Shi J, Langer R, Farokhzad OC. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol Biol 2010;629:53-67. [PMID: 20387142 DOI: 10.1007/978-1-60761-657-3_4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
64 Yang N, Mahato RI. GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis. Pharm Res. 2011;28:752-761. [PMID: 21347569 DOI: 10.1007/s11095-011-0384-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
65 Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol 2008;26:552-8. [PMID: 18722682 DOI: 10.1016/j.tibtech.2008.06.007] [Cited by in Crossref: 255] [Cited by in F6Publishing: 237] [Article Influence: 18.2] [Reference Citation Analysis]
66 Basu I, Maiti PK. Insight into the Mechanism of Carrier-Mediated Delivery of siRNA in the Cell Membrane Using MD Simulation. Langmuir 2021;37:266-77. [PMID: 33369423 DOI: 10.1021/acs.langmuir.0c02871] [Reference Citation Analysis]
67 Metelev V, Zhang S, Zheng S, Kumar ATN, Bogdanov A Jr. Fluorocarbons Enhance Intracellular Delivery of Short STAT3-sensors and Enable Specific Imaging. Theranostics 2017;7:3354-68. [PMID: 28900515 DOI: 10.7150/thno.19704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
68 Landry B, Valencia-serna J, Gul-uludag H, Jiang X, Janowska-wieczorek A, Brandwein J, Uludag H. Progress in RNAi-mediated Molecular Therapy of Acute and Chronic Myeloid Leukemia. Molecular Therapy - Nucleic Acids 2015;4:e240. [DOI: 10.1038/mtna.2015.13] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
69 Kruglova NS, Meschaninova MI, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. Cholesterol-modified anti-MDR1 small interfering RNA: Uptake and biological activity. Mol Biol 2010;44:254-61. [DOI: 10.1134/s002689331002010x] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
70 Portet A, Galinier R, Lassalle D, Faille A, Gourbal B, Duval D. Hemocyte siRNA uptake is increased by 5' cholesterol-TEG addition in Biomphalaria glabrata, snail vector of schistosome. PeerJ 2021;9:e10895. [PMID: 33665030 DOI: 10.7717/peerj.10895] [Reference Citation Analysis]
71 Gudipati S, Zhang K, Rouge JL. Towards Self-Transfecting Nucleic Acid Nanostructures for Gene Regulation. Trends in Biotechnology 2019;37:983-94. [DOI: 10.1016/j.tibtech.2019.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
72 Apparailly F, Jorgensen C. siRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol 2013;9:56-62. [DOI: 10.1038/nrrheum.2012.176] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
73 Rata-aguilar A, Segovia-ramos N, Jódar-reyes AB, Ramos-pérez V, Borrós S, Ortega-vinuesa JL, Martín-rodríguez A. The role of hydrophobic alkyl chains in the physicochemical properties of poly(β-amino ester)/DNA complexes. Colloids and Surfaces B: Biointerfaces 2015;126:374-80. [DOI: 10.1016/j.colsurfb.2014.11.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
74 Bhat M, Jatyan R, Mittal A, Mahato RI, Chitkara D. Opportunities and challenges of fatty acid conjugated therapeutics. Chem Phys Lipids 2021;236:105053. [PMID: 33484709 DOI: 10.1016/j.chemphyslip.2021.105053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Shu Y, Cinier M, Shu D, Guo P. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods 2011;54:204-14. [PMID: 21320601 DOI: 10.1016/j.ymeth.2011.01.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
76 Chang Kang H, Bae YH. Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide. Biomaterials 2011;32:4914-24. [PMID: 21489622 DOI: 10.1016/j.biomaterials.2011.03.042] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
77 Lokras A, Thakur A, Wadhwa A, Thanki K, Franzyk H, Foged C. Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles. Front Bioeng Biotechnol 2020;8:601155. [PMID: 33520957 DOI: 10.3389/fbioe.2020.601155] [Reference Citation Analysis]
78 Binzel DW, Khisamutdinov EF, Guo P. Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments. Biochemistry 2014;53:2221-31. [PMID: 24694349 DOI: 10.1021/bi4017022] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
79 Kubo T, Yanagihara K, Seyama T. In Vivo RNAi Efficacy of Palmitic Acid-Conjugated Dicer-Substrate siRNA in a Subcutaneous Tumor Mouse Model. Chem Biol Drug Des 2016;87:811-23. [DOI: 10.1111/cbdd.12720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Kundu AK, Iyer SV, Chandra S, Adhikari AS, Iwakuma T, Mandal TK. Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. PLoS One 2017;12:e0179168. [PMID: 28636657 DOI: 10.1371/journal.pone.0179168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
81 Cavallaro G, Licciardi M, Scirè S, Giammona G. Microwave-assisted synthesis of PHEA–oligoamine copolymers as potential gene delivery systems. Nanomedicine 2009;4:291-303. [DOI: 10.2217/nnm.09.7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
82 Stegh AH. Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) 2013;5:48-65. [PMID: 22858688 DOI: 10.1039/c2ib20104f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
83 Singh S, Narang AS, Mahato RI. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res. 2011;28:2996-3015. [PMID: 22033880 DOI: 10.1007/s11095-011-0608-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 106] [Article Influence: 11.1] [Reference Citation Analysis]
84 Zhu L, Perche F, Wang T, Torchilin VP. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials 2014;35:4213-22. [PMID: 24529391 DOI: 10.1016/j.biomaterials.2014.01.060] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 18.1] [Reference Citation Analysis]
85 Petrova Kruglova NS, Meschaninova MI, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. 2'-O-methyl-modified anti-MDR1 fork-siRNA duplexes exhibiting high nuclease resistance and prolonged silencing activity. Oligonucleotides 2010;20:297-308. [PMID: 21028964 DOI: 10.1089/oli.2010.0246] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
86 McGinnis AC, Chen B, Bartlett MG. Chromatographic methods for the determination of therapeutic oligonucleotides. J Chromatogr B Analyt Technol Biomed Life Sci 2012;883-884:76-94. [PMID: 21945211 DOI: 10.1016/j.jchromb.2011.09.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
87 Yujie X, Dengfeng G, Zhongwei L, Xiaolin N. microRNAs in heart failure: . Chinese Medical Journal 2014;127:3328-34. [DOI: 10.1097/00029330-201409200-00024] [Reference Citation Analysis]
88 Seth PP, Allerson CR, Siwkowski A, Vasquez G, Berdeja A, Migawa MT, Gaus H, Prakash TP, Bhat B, Swayze EE. Configuration of the 5'-methyl group modulates the biophysical and biological properties of locked nucleic acid (LNA) oligonucleotides. J Med Chem. 2010;53:8309-8318. [PMID: 21058707 DOI: 10.1021/jm101207e] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
89 Ruigrok MJR, Maggan N, Willaert D, Frijlink HW, Melgert BN, Olinga P, Hinrichs WLJ. siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney. AAPS J 2017;19:1855-63. [PMID: 28895093 DOI: 10.1208/s12248-017-0136-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
90 Petrova NS, Chernikov IV, Meschaninova MI, Dovydenko IS, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res 2012;40:2330-44. [PMID: 22080508 DOI: 10.1093/nar/gkr1002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
91 Glebova KV, Marakhonov AV, Baranova AV, Skoblov MY. Therapeutic siRNAs and nonviral systems for their delivery. Mol Biol 2012;46:335-48. [DOI: 10.1134/s0026893312020069] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 Falamarzian A, Xiong X, Uludag H, Lavasanifar A. Polymeric micelles for siRNA delivery. Journal of Drug Delivery Science and Technology 2012;22:43-54. [DOI: 10.1016/s1773-2247(12)50004-3] [Cited by in Crossref: 18] [Article Influence: 1.8] [Reference Citation Analysis]
93 Parakh S, Parslow AC, Gan HK, Scott AM. Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opin Drug Deliv 2016;13:401-19. [PMID: 26654403 DOI: 10.1517/17425247.2016.1124854] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
94 David S, Pitard B, Benoît J, Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacological Research 2010;62:100-14. [DOI: 10.1016/j.phrs.2009.11.013] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 6.2] [Reference Citation Analysis]
95 Jivrajani M, Nivsarkar M. Ligand-targeted bacterial minicells: Futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells. Nanomedicine 2016;12:2485-98. [PMID: 27378204 DOI: 10.1016/j.nano.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
96 Raemdonck K, Vandenbroucke RE, Demeester J, Sanders NN, De Smedt SC. Maintaining the silence: reflections on long-term RNAi. Drug Discov Today 2008;13:917-31. [PMID: 18620073 DOI: 10.1016/j.drudis.2008.06.008] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
97 Hickerson RP, Vlassov AV, Wang Q, Leake D, Ilves H, Gonzalez-Gonzalez E, Contag CH, Johnston BH, Kaspar RL. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008;18:345-54. [PMID: 18844576 DOI: 10.1089/oli.2008.0149] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.8] [Reference Citation Analysis]
98 Rasmussen KF, Smith AA, Ruiz-Sanchis P, Edlund K, Zelikin AN. Cholesterol modification of (Bio)polymers using UV-Vis traceable chemistry in aqueous solutions. Macromol Biosci 2014;14:33-44. [PMID: 24106046 DOI: 10.1002/mabi.201300286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
99 Hao L, Patel PC, Alhasan AH, Giljohann DA, Mirkin CA. Nucleic acid-gold nanoparticle conjugates as mimics of microRNA. Small. 2011;7:3158-3162. [PMID: 21922667 DOI: 10.1002/smll.201101018] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 6.5] [Reference Citation Analysis]
100 Cuestas ML, Glisoni RJ, Mathet VL, Sosnik A. Lactosylated poly(ethylene oxide)–poly(propylene oxide) block copolymers for potential active targeting: synthesis and physicochemical and self-aggregation characterization. J Nanopart Res 2013;15. [DOI: 10.1007/s11051-012-1389-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
101 Dan N, Danino D. Structure and kinetics of lipid–nucleic acid complexes. Advances in Colloid and Interface Science 2014;205:230-9. [DOI: 10.1016/j.cis.2014.01.013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
102 Loczenski Rose V, Winkler GS, Allen S, Puri S, Mantovani G. Polymer siRNA conjugates synthesised by controlled radical polymerisation. European Polymer Journal 2013;49:2861-83. [DOI: 10.1016/j.eurpolymj.2013.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
103 Cerda MB, Batalla M, Anton M, Cafferata E, Podhajcer O, Plank C, Mykhaylyk O, Policastro L. Enhancement of nucleic acid delivery to hard-to-transfect human colorectal cancer cells by magnetofection at laminin coated substrates and promotion of the endosomal/lysosomal escape. RSC Adv 2015;5:58345-54. [DOI: 10.1039/c5ra06562c] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
104 López-Fraga M, Martínez T, Jiménez A. RNA interference technologies and therapeutics: from basic research to products. BioDrugs 2009;23:305-32. [PMID: 19754220 DOI: 10.2165/11318190-000000000-00000] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
105 Fisher M, Abramov M, Van Aerschot A, Rozenski J, Dixit V, Juliano RL, Herdewijn P. Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur J Pharmacol 2009;606:38-44. [PMID: 19374843 DOI: 10.1016/j.ejphar.2009.01.030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
106 Mantei A, Rutz S, Janke M, Kirchhoff D, Jung U, Patzel V, Vogel U, Rudel T, Andreou I, Weber M, Scheffold A. siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur J Immunol 2008;38:2616-25. [DOI: 10.1002/eji.200738075] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
107 Gvozdeva OV, Prassolov VS, Zenkova MA, Vlassov VV, Chernolovskaya EL. Silencing of Inducible Immunoproteasome Subunit Expression by Chemically Modified siRNA and shRNA. Nucleosides Nucleotides Nucleic Acids 2016;35:389-403. [PMID: 27351110 DOI: 10.1080/15257770.2016.1184275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
108 Rattanakiat S, Nishikawa M, Takakura Y. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation. Eur J Pharm Sci 2012;47:352-8. [PMID: 22771546 DOI: 10.1016/j.ejps.2012.06.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
109 Ono M, Yamada K, Endo A, Avolio F, Lamond AI. Analysis of human protein replacement stable cell lines established using snoMEN-PR vector. PLoS One 2013;8:e62305. [PMID: 23638031 DOI: 10.1371/journal.pone.0062305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
110 Bang E, Kim BH. Synthesis of hairpin siRNA using 18β-glycyrrhetinic acid derivative as a loop motif. Tetrahedron Letters 2009;50:2545-7. [DOI: 10.1016/j.tetlet.2009.03.049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Bruno K. Using drug-excipient interactions for siRNA delivery. Adv Drug Deliv Rev 2011;63:1210-26. [PMID: 21945846 DOI: 10.1016/j.addr.2011.09.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
112 Perlini LE, Szczurkowska J, Ballif BA, Piccini A, Sacchetti S, Giovedì S, Benfenati F, Cancedda L. Synapsin III acts downstream of semaphorin 3A/CDK5 signaling to regulate radial migration and orientation of pyramidal neurons in vivo. Cell Rep 2015;11:234-48. [PMID: 25843720 DOI: 10.1016/j.celrep.2015.03.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
113 Li F, Mahato RI. Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J Gene Med 2009;11:764-71. [PMID: 19554613 DOI: 10.1002/jgm.1357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
114 Tsujiuchi T, Miller AD, Wakabayashi T, Natsume A. RNA Interference Therapeutics for Tumor Therapy. Gene Therapy of Cancer. Elsevier; 2014. pp. 393-408. [DOI: 10.1016/b978-0-12-394295-1.00027-5] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
115 Liu J, Guo S, Cinier M, Shlyakhtenko LS, Shu Y, Chen C, Shen G, Guo P. Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano 2011;5:237-46. [PMID: 21155596 DOI: 10.1021/nn1024658] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
116 Wada S, Obika S, Shibata MA, Yamamoto T, Nakatani M, Yamaoka T, Torigoe H, Harada-Shiba M. Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo. Mol Ther Nucleic Acids 2012;1:e45. [PMID: 23344237 DOI: 10.1038/mtna.2012.32] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
117 Guo P, Coban O, Snead NM, Trebley J, Hoeprich S, Guo S, Shu Y. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 2010;62:650-66. [PMID: 20230868 DOI: 10.1016/j.addr.2010.03.008] [Cited by in Crossref: 184] [Cited by in F6Publishing: 164] [Article Influence: 15.3] [Reference Citation Analysis]
118 Salim L, Mckim C, Desaulniers J. Effective carrier-free gene-silencing activity of cholesterol-modified siRNAs. RSC Adv 2018;8:22963-6. [DOI: 10.1039/c8ra03908a] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Snead NM, Rossi JJ. Biogenesis and function of endogenous and exogenous siRNAs. Wiley Interdiscip Rev RNA 2010;1:117-31. [PMID: 21956909 DOI: 10.1002/wrna.14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
120 Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2:305-15. [PMID: 20135697 DOI: 10.1002/wnan.81] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 6.8] [Reference Citation Analysis]
121 Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm 2008;5:622-31. [PMID: 18461969 DOI: 10.1021/mp8000233] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 7.3] [Reference Citation Analysis]
122 Leite-Moreira AM, Lourenço AP, Falcão-Pires I, Leite-Moreira AF. Pivotal role of microRNAs in cardiac physiology and heart failure. Drug Discov Today 2013;18:1243-9. [PMID: 23954179 DOI: 10.1016/j.drudis.2013.07.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
123 Miller AD. Delivering the promise of small ncRNA therapeutics. Therapeutic Delivery 2014;5:569-89. [DOI: 10.4155/tde.14.23] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
124 Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010;267:9-21. [PMID: 20059641 DOI: 10.1111/j.1365-2796.2009.02189.x] [Cited by in Crossref: 305] [Cited by in F6Publishing: 288] [Article Influence: 25.4] [Reference Citation Analysis]
125 Chatelain G, Schepers G, Rozenski J, Van Aerschot A. Hybridization potential of oligonucleotides comprising 3'-O-methylated altritol nucleosides. Mol Divers 2012;16:825-37. [PMID: 23054535 DOI: 10.1007/s11030-012-9402-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
126 Lim Y, Lee E, Yoon Y, Lee M, Lee M. Filamentous Artificial Virus from a Self-Assembled Discrete Nanoribbon. Angew Chem 2008;120:4601-4. [DOI: 10.1002/ange.200800266] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
127 Dan N. Structure and kinetics of synthetic, lipid-based nucleic acid carriers. Lipid Nanocarriers for Drug Targeting. Elsevier; 2018. pp. 529-62. [DOI: 10.1016/b978-0-12-813687-4.00014-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Cheung W, Pontoriero F, Taratula O, Chen AM, He H. DNA and carbon nanotubes as medicine. Advanced Drug Delivery Reviews 2010;62:633-49. [DOI: 10.1016/j.addr.2010.03.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 109] [Article Influence: 11.3] [Reference Citation Analysis]
129 Gao Y, Liu W, Gao H, Qi X, Lin H, Wang X, Shen R. Effective inhibition of infectious bursal disease virus replication in vitro by DNA vector-based RNA interference. Antiviral Res 2008;79:87-94. [PMID: 18378010 DOI: 10.1016/j.antiviral.2007.11.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
130 Cho IS, Kim J, Lim DH, Ahn H, Kim H, Lee K, Lee YS. Improved serum stability and biophysical properties of siRNAs following chemical modifications. Biotechnol Lett 2008;30:1901-8. [DOI: 10.1007/s10529-008-9776-4] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
131 Kang MR, Li G, Pan T, Xing JC, Li LC. Development of Therapeutic dsP21-322 for Cancer Treatment. Adv Exp Med Biol 2017;983:217-29. [PMID: 28639203 DOI: 10.1007/978-981-10-4310-9_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
132 Barik S, Lu P. Therapy of respiratory viral infections with intranasal siRNAs. Methods Mol Biol 2015;1218:251-62. [PMID: 25319655 DOI: 10.1007/978-1-4939-1538-5_14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
133 Wu Z, Chien C, Liu C, Yan J, Lin S. Recent progress in copolymer-mediated siRNA delivery. Journal of Drug Targeting 2012;20:551-60. [DOI: 10.3109/1061186x.2012.699057] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
134 Panebianco F, Climent M, Malvindi MA, Pompa PP, Bonetti P, Nicassio F. Delivery of biologically active miR-34a in normal and cancer mammary epithelial cells by synthetic nanoparticles. Nanomedicine 2019;19:95-105. [PMID: 31028887 DOI: 10.1016/j.nano.2019.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
135 Depieri LV, Borgheti-Cardoso LN, Campos PM, Otaguiri KK, Vicentini FT, Lopes LB, Fonseca MJ, Bentley MV. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase. Eur J Pharm Biopharm 2016;105:50-8. [PMID: 27224855 DOI: 10.1016/j.ejpb.2016.05.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
136 Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, Xu X, Huang C, Huang W, Dong J, Li L, Liu J, Shen G, Tu Y. Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther 2009;17:269-77. [PMID: 19066596 DOI: 10.1038/mt.2008.266] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
137 Chernikov IV, Vlassov VV, Chernolovskaya EL. Current Development of siRNA Bioconjugates: From Research to the Clinic. Front Pharmacol 2019;10:444. [PMID: 31105570 DOI: 10.3389/fphar.2019.00444] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 20.0] [Reference Citation Analysis]
138 Froehlich E, Mandeville JS, Kreplak L, Tajmir-Riahi HA. Aggregation and particle formation of tRNA by dendrimers. Biomacromolecules 2011;12:2780-7. [PMID: 21574643 DOI: 10.1021/bm200547e] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
139 Chernolovskaya EL, Zenkova MA. Design of nuclease-resistant fork-like small interfering RNA (fsiRNA). Methods Mol Biol 2013;942:153-68. [PMID: 23027050 DOI: 10.1007/978-1-62703-119-6_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Patel PC, Hao L, Yeung WS, Mirkin CA. Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs. Mol Pharm 2011;8:1285-91. [PMID: 21630673 DOI: 10.1021/mp200084y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
141 Sempere LF, Kauppinen S. Translational Implications of MicroRNAs in Clinical Diagnostics and Therapeutics. Handbook of Cell Signaling. Elsevier; 2010. pp. 2965-81. [DOI: 10.1016/b978-0-12-374145-5.00340-5] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
142 Koutsaki M, Spandidos DA, Zaravinos A. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 2014;351:173-81. [PMID: 24952258 DOI: 10.1016/j.canlet.2014.05.022] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 9.9] [Reference Citation Analysis]
143 Dan N; Department of Chemical and Biological Engineering, Drexel University, Philadelphia, PA, 19104, USA. . AIMS Biophysics 2015;2:163-83. [DOI: 10.3934/biophy.2015.2.163] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
144 Cao M, Deng X, Su S, Zhang F, Xiao X, Hu Q, Fu Y, Yang BB, Wu Y, Sheng W, Zeng Y. Protamine sulfate–nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells. Nanoscale 2013;5:12120. [DOI: 10.1039/c3nr04056a] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
145 Gissot A, Camplo M, Grinstaff MW, Barthélémy P. Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids. Org Biomol Chem 2008;6:1324-33. [PMID: 18385837 DOI: 10.1039/b719280k] [Cited by in Crossref: 142] [Cited by in F6Publishing: 126] [Article Influence: 10.1] [Reference Citation Analysis]
146 Borgheti-Cardoso LN, Viegas JSR, Silvestrini AVP, Caron AL, Praça FG, Kravicz M, Bentley MVLB. Nanotechnology approaches in the current therapy of skin cancer. Adv Drug Deliv Rev 2020;153:109-36. [PMID: 32113956 DOI: 10.1016/j.addr.2020.02.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
147 Miller AD. Delivery of RNAi therapeutics: work in progress. Expert Rev Med Devices 2013;10:781-811. [PMID: 24195461 DOI: 10.1586/17434440.2013.855471] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
148 Singh Y, Murat P, Defrancq E. Recent developments in oligonucleotide conjugation. Chem Soc Rev 2010;39:2054-70. [PMID: 20393645 DOI: 10.1039/b911431a] [Cited by in Crossref: 177] [Cited by in F6Publishing: 148] [Article Influence: 14.8] [Reference Citation Analysis]
149 Yu C, An M, Li M, Liu H. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides. Mol Pharm 2017;14:2815-23. [PMID: 28686452 DOI: 10.1021/acs.molpharmaceut.7b00335] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
150 Chen Q, Butler D, Querbes W, Pandey RK, Ge P, Maier MA, Zhang L, Rajeev KG, Nechev L, Kotelianski V, Manoharan M, Sah DW. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 2010;144:227-32. [PMID: 20170694 DOI: 10.1016/j.jconrel.2010.02.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
151 Chitkara D, Mittal A, Mahato RI. miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. Adv Drug Deliv Rev 2015;81:34-52. [PMID: 25252098 DOI: 10.1016/j.addr.2014.09.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
152 Mescalchin A, Detzer A, Wecke M, Overhoff M, Wünsche W, Sczakiel G. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery. Expert Opin Biol Ther 2007;7:1531-8. [PMID: 17916045 DOI: 10.1517/14712598.7.10.1531] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
153 Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36:4158-71. [PMID: 18558618 DOI: 10.1093/nar/gkn342] [Cited by in Crossref: 300] [Cited by in F6Publishing: 272] [Article Influence: 21.4] [Reference Citation Analysis]
154 Ugarte-Uribe B, Grijalvo S, Busto JV, Martín C, Eritja R, Goñi FM, Alkorta I. Double-tailed lipid modification as a promising candidate for oligonucleotide delivery in mammalian cells. Biochim Biophys Acta 2013;1830:4872-84. [PMID: 23800579 DOI: 10.1016/j.bbagen.2013.06.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
155 Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem 2010;21:2119-27. [PMID: 20964335 DOI: 10.1021/bc100346n] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
156 Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR, Azizi H, Torkamandi S, Tavakkoly-Bazzaz J. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther 2017;24:233-43. [PMID: 28574057 DOI: 10.1038/cgt.2017.16] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 7.2] [Reference Citation Analysis]
157 Wang LL, Burdick JA. Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies. Adv Healthc Mater 2017;6. [PMID: 27976524 DOI: 10.1002/adhm.201601041] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
158 Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 2009;6:686-95. [PMID: 19397332 DOI: 10.1021/mp900093r] [Cited by in Crossref: 204] [Cited by in F6Publishing: 190] [Article Influence: 15.7] [Reference Citation Analysis]
159 Oskuee RK, Mohtashami E, Golami L, Malaekeh-nikouei B. Cationic liposomes-polyallylamine-plasmid nanocomplexes for gene delivery. Journal of Experimental Nanoscience 2013;9:1026-34. [DOI: 10.1080/17458080.2013.771245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
160 Watanabe K, Harada-Shiba M, Suzuki A, Gokuden R, Kurihara R, Sugao Y, Mori T, Katayama Y, Niidome T. In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. Mol Biosyst 2009;5:1306-10. [PMID: 19823746 DOI: 10.1039/b900880b] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
161 Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012;33:7138-50. [DOI: 10.1016/j.biomaterials.2012.06.068] [Cited by in Crossref: 229] [Cited by in F6Publishing: 201] [Article Influence: 22.9] [Reference Citation Analysis]